期刊文献+

肿瘤免疫耐受——树突状细胞的免疫耐受 被引量:3

原文传递
导出
摘要 第七期"热点评析"栏目谈了肿瘤细胞本身的免疫学特性[1],说明肿瘤细胞具有"免疫逃逸功能",不受患者体内免疫系统的监督。这仅说明肿瘤免疫耐受的一个方面,更为重要的是患者自身免疫系统在肿瘤及其周围基质细胞的影响和调教下产生了对肿瘤的退让、和平共处、甚至助纣为虐的作用。例如,
作者 郭礼和
出处 《中国细胞生物学学报》 CAS CSCD 北大核心 2012年第9期946-950,共5页 Chinese Journal of Cell Biology
  • 引文网络
  • 相关文献

参考文献9

  • 1郭礼和.肿瘤免疫耐受——肿瘤细胞的免疫学特性[J].中国细胞生物学学报,2012,34(7):732-734. 被引量:3
  • 2赖东梅,郭礼和.炎性单核细胞促进乳腺癌转移的分子机制[J].中国细胞生物学学报,2011,33(8):948-949. 被引量:2
  • 3Dumitriu IE, Dunbar DR, Howie SE, Sethi T, Gregory CD. Human dendritic cells produce TGF-beta l under the influ- ence of lung carcinoma cells and prime the differentiation of CD4+CD256Foxp3+ regulatory T cells. J lmmunol 2009; 182(5): 2795-807.
  • 4Idoyaga J, Moreno J, Bonifaz L. Tumor cells prevent mouse den- dritic cell maturation induced by TLR ligands. Cancer Immunol lmmunother 2007; 56(8): 1237-50.
  • 5Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G. lmiquimod in basal cell carcinoma: How does it work? Br J Der- matol 2003; 149 Suppl 66: 57-8.
  • 6Shen L, Evel-Kabier K, Strube R, Chen SY. Silencing of SOCSI enhances antigen presentation by dendritic cells and antigen-specif- ic anti-tumor immunity. Nat Biotechnol 2004; 22(12): 1546-53.
  • 7Herber DL, Can W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med 2010; 16(8): 880-6.
  • 8Zitvogel L, Kroemer G. Targeting dendritic cell metabolism in cancer. Nat Med 2010; 16(8): 858-9.
  • 9Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar- Fadul X, Baird J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209(3): 495-506.

二级参考文献1

  • 1Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast- tumour metastasis. Nature 201 l; doi: 10.1038/nature10138.

共引文献3

同被引文献53

  • 1曾四平,肖亚军.肿瘤浸润性树突状细胞与前列腺癌病理分级及临床分期的关系[J].临床泌尿外科杂志,2004,19(10):617-618. 被引量:1
  • 2唐丽萍,娄阁,隋丽华,王晶,马荣.宫颈癌中树突细胞浸润对临床预后影响的研究[J].中国现代医学杂志,2006,16(19):2944-2946. 被引量:2
  • 3HANAHAN D, WEINBERG R A. Hallmarks of cancer: the next generation [ J ]. Cell,2011,144 (5) :646-674.
  • 4BALACHANDRAN V P, CAVNAR M J, ZENG S, et al. Imatinib potentiates antitumor T cell responses in gastro- intestinal stromal tumor through the inhibition of Ido [ J ]. Nat Med,2011,17(9) :1094-1100.
  • 5ZITVOGEL L, KEPP O, KROEMER G. Immune parame- ters affecting the efficacy of chemotherapeutic regimens [J]. Nat Rev Clin Oncol,2011,8(3) :151-160.
  • 6ANTONY P A, RESTIFO N P. CD4 CD25 T regulatory cells, immunotherapy of cancer, and interleukin-2 [ J ]. J Immunother, 2005,28 (2) : 120 -128.
  • 7GAI X D, LI C, SONG Y, et al. In situ analysis of FOXP3 + regulatory T ceils and myeloid dendritic ceils in hu- man colorectal cancer tissue and tumor-draining lymph node[ J]. Biomed Rep,2013,1 (2) :207-212.
  • 8TANG Y, XU X, GUO S, et al. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarci- noma[ J]. PLoS One,2014,9(3 ) :e91551.
  • 9ZOU W. Regulatory T cells, tumour immunity and immu- notherapy[ J]. Nat Rev Immunol,2006,6(4):295-307.
  • 10WHITESIDE T L. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progres- sion? [ J ] Cancer Immunol Immunother, 2014,63 ( 1 ) : 67-72.

引证文献3

二级引证文献26

;
使用帮助 返回顶部